US OptionsDetailed Quotes
PFE250502P24500
- 0.62
- -1.05-62.87%
15min DelayTrading Apr 29 13:59 ET
1.21High0.50Low
1.21Open1.67Pre Close206 Volume23 Open Interest24.50Strike Price13.99KTurnover25.15%IV0.21%PremiumMay 2, 2025Expiry Date0.57Intrinsic Value100Multiplier3DDays to Expiry0.05Extrinsic Value100Contract SizeAmericanOptions Type-0.8680Delta0.4029Gamma38.29Leverage Ratio-0.0164Theta-0.0014Rho-33.23Eff Leverage0.0047Vega
Pfizer Stock Discussion
The stock finally breaks above 24. If the price can stay above 24, the uptrend momentum will be sustainable.
Big green candle. Next resistance is 24.10. Once it breaks the resistance, next hit point will be 24.28. The stock is trading above 5 EMA, 10 EMA and 20 EMA but below 60 EMA. The trend is up and bullish.
$Pfizer (PFE.US)$'s stock rose Tuesday after the drug manufacturer said it's trending toward the higher end of its 2025 profit projections.
Pfizer also beat analyst expectations for first-quarter earnings as it benefited from cost-saving efforts, although it fell short of Wall Street's revenue estimate, as sales of its COVID-19 medicine Paxlovid plunged by 75% on fading demand.
"Our focus on operational efficiency and financial discipline is driving strong results to our bottom l...
Breakthrough: Pfizer's New Bladder Cancer Treatment First Major Advance in 30 Years - See 91% Success Rate
Pfizer (PFE) announced results from the pivotal Phase 3 CREST trial of sasanlimab, an investigational anti-PD-1 monoclonal antibody, in combination with standard of care Bacillus Calmette-Guerin as induction therapy with or without maintenance in patients with BCG-naive, high-risk non-muscle invasive bladder cancer, NMIBC. The trial met its primary endpoint of event-free survival, EFS, by investigator assessment, demonstrating a clinically meaningful and statistically significan...
get done once, just once a 100%
$Johnson & Johnson (JNJ.US)$
$Pfizer (PFE.US)$
$E-mini NASDAQ 100 Futures(JUN5) (NQmain.US)$
$E-mini S&P 500 Futures(JUN5) (ESmain.US)$
No comment yet